Loading
ACE-232 is an experimental oral small-molecule enzyme inhibitor from Acerand Therapeutics, in phase 1 trials for metastatic castration-resistant prostate cancer.
ACE-232 is an oral small-molecule enzyme inhibitor from Acerand Therapeutics. An oral inhibitor of CYP11A1, the enzyme at the first step of steroid hormone production, given with dexamethasone and fludrocortisone. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.
An oral inhibitor of CYP11A1, the enzyme at the first step of steroid hormone production, given with dexamethasone and fludrocortisone. Connects to CYP11A1 (cholesterol side-chain cleavage enzyme).
1.ACE-232 binds CYP11A1 (cholesterol side-chain cleavage enzyme).
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ACE-232" OR ABSTRACT:"ACE-232") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACE-232, not a curated reading list.
Shares CYP11A1 (cholesterol side-chain cleavage enzyme), Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Acerand Therapeutics and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/